Gene-targeted therapies, such as adeno-associated viral vector (AAV)-mediated gene
therapy and cell-mediated therapy using myogenic stem cells, are hopeful molecular …

Myostatin is a potent negative regulator of skeletal muscle growth. Therefore, myostatin
inhibition offers a novel therapeutic strategy for muscular dystrophy by restoring skeletal …

Follistatin is a functional antagonist of several members of the TGF-β family of secreted
signaling factors, including myostatin, the most powerful inhibitor of muscle growth …

In addition to gene correction therapy and cell transplantation techniques, multidisciplinary
approaches to drug discovery and development offer promising therapeutic strategies for …

Follistatin (FS) inhibits several members of the TGF-β superfamily, including myostatin
(Mstn), a negative regulator of muscle growth. Mstn inhibition by FS represents a potential …

Background Myostatin antagonists are being developed as therapies for Duchenne
muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered …

Antagonists of myostatin, a blood-borne negative regulator of muscle growth produced in
muscle cells, have shown considerable promise for enhancing muscle mass and strength in …

Muscular dystrophies are characterized by weakness and wasting of skeletal muscle
tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to …

Myostatin, a member of the transforming growth factor (TGF)-β superfamily, plays a potent
inhibitory role in regulating skeletal muscle mass. Inhibition of myostatin by gene disruption …

In most cases, pharmacologic strategies to treat genetic muscle disorders and certain
acquired disorders, such as sporadic inclusion body myositis, have produced modest …